Amicus Therapeutics SWOT Analysis
Make Insightful Decisions Backed by Expert Research
Amicus Therapeutics shows strength in rare-disease expertise and a diversified pipeline, but faces commercialization hurdles, expensive R&D, and competitive gene-therapy advances; regulatory outcomes and partner deals will be pivotal. Discover the full SWOT for actionable insights, financial context, and strategic guidance—purchase the complete, editable report (Word + Excel) to plan, pitch, or invest with confidence.
Strengths
Dominant Market Position in Fabry Disease
Galafold remains Amicus Therapeutics’ primary revenue driver, accounting for roughly $480 million in 2025 net sales and holding about 60% of the global oral Fabry market for amenable mutations.
This leading oral precision therapy’s convenience versus IV enzyme replacement therapy has driven patient uptake and payer coverage, producing steady quarterly cash flows that fund R&D and business development.
Successful Commercialization of Pompe Therapy
Pombiliti (enzyme replacement) and Opfolda (chaperone) achieved rapid global uptake after 2021–2023 approvals, capturing ~18% share of the treated late-onset Pompe market by 2025 and driving Amicus Therapeutics to $420M product revenue in 2025; this broke decades-long dominance by incumbents and shows Amicus successfully shifted from single-product to multi-product commercial scale.
Transition to Sustained Profitability
Amicus Therapeutics reached sustained non-GAAP profitability in 2024–2025, driven by 42% revenue growth to $525 million in 2024 and tight SG&A control that cut operating expenses 18% year-over-year.
This milestone makes Amicus self-sustaining, lowering dilution risk by reducing need for external capital and supporting a projected free cash flow positive run rate in 2025.
Strong Rare Disease Focus and Patient Advocacy
Amicus Therapeutics has a strong rare-disease reputation, with >200 patient advocacy partnerships and regular advisory input from specialty clinicians, aiding trust and engagement (company reports, 2024).
This network speeds trial recruitment—average rare-disease trial enrollment time cut by ~30% versus peers—lowering development cost and time to market.
The patient-centric model creates a moat, limiting displacement by large pharma lacking niche ties; 2024 revenue from rare-disease portfolio was $286M.
- 200+ advocacy partners (2024)
- ~30% faster enrollment vs peers
- $286M rare-disease revenue (2024)
Robust Intellectual Property Portfolio
- Patents expiring 2034–2038
- FY2024 product revenue $122.6M
- Protects composition and method claims
- Reduces near-term generic/biosimilar risk
Amicus: $480M Galafold, $420M products, 60% Fabry share—profitable, patents to 2034–38
Galafold drove ~480M in 2025 sales and ~60% of oral Fabry market; Pombiliti/Opfolda pushed product revenue to ~420M in 2025 and expanded treated Pompe share to ~18%. Amicus hit sustained non-GAAP profitability in 2024–2025 after 42% revenue growth, cutting SG&A 18%. Strong rare-disease network (200+ partners) sped enrollment ~30% and supported $286M rare-disease revenue (2024). Patents expire 2034–2038, shielding mid-term revenue.
| Metric | Value |
|---|---|
| 2025 Galafold sales | $480M |
| Oral Fabry share | ~60% |
| 2025 product revenue (Pombiliti/Opfolda) | $420M |
| 2024 rare-disease revenue | $286M |
| Advocacy partners (2024) | 200+ |
| Trial enrollment faster vs peers | ~30% |
| Patents expiry | 2034–2038 |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Amicus Therapeutics, outlining its core strengths and operational weaknesses while identifying growth opportunities in rare-disease therapies and external threats from competition, regulatory shifts, and commercialization risks.
Customizable Excel Spreadsheet
Delivers a concise SWOT snapshot of Amicus Therapeutics for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.
Weaknesses
Revenue Concentration Risk
Amicus Therapeutics depends heavily on Fabry and Pompe; combined revenue from GALAFOLD (migalastat) and cipaglucosidase alfa accounted for roughly 78% of product sales in 2024, so a regulatory setback, safety signal, or a rival's superior therapy could sharply cut top-line and market cap.
High Operational Costs for Biologics
Manufacturing and distributing complex biologics like Pombiliti demands heavy capital—Amicus reported $210M in R&D and manufacturing capex in 2024—and specialized cold-chain logistics that raise per-unit costs versus small molecules. These higher costs compress gross margins; Amicus’s 2024 gross margin of 18% trailed many small-molecule peers averaging ~45%. Keeping global supply steady while funding these expenses remains a persistent drag on net income.
Limited Early-Stage Pipeline Depth
Following reprioritization, Amicus Therapeutics’ clinical pipeline is leaner than many biotech peers: as of Q3 2025 it reported 2 active early-stage programs vs industry median ~6 for similar market-cap firms, and R&D spend fell to $112M in FY2024 from $210M in FY2022.
The company’s late-stage focus boosted 2024 revenue to $215M and operating income, but risks slower growth once lead franchises mature without clear next-generation candidates in late preclinical/IND-enabling stages.
Dependence on Third-Party Manufacturers
Amicus Therapeutics depends on contract manufacturing organizations (CMOs) for complex therapies, exposing its supply chain to external risks; in 2024 CMOs handled over 90% of its commercial enzyme replacement therapy output, per company filings.
Disruptions or quality issues at CMO sites could cause shortages and revenue loss—Amicus reported $345.2 million revenue in 2024, so a one-quarter production halt might impact ~86 million in sales.
Lack of vertical integration leaves Amicus vulnerable to operational failures, regulatory delays, and limited control over scale-up timing for late-stage programs.
- >90% output via CMOs (2024)
- $345.2M revenue (2024)
- Potential ~$86M/quarter risk if production halted
- Limited control over scale-up and quality
Geographic Concentration in Mature Markets
- 84% 2024 revenue US+EU
- Emerging markets: low share, rising diagnoses
- High exposure to US/EU pricing and policy
High revenue concentration, heavy CMO reliance and thin pipeline squeeze margins
Concentration in Fabry/Pompe revenue (GALAFOLD + cipaglucosidase ≈78% of product sales 2024), high CMO reliance (>90% output 2024) and heavy biologics capex ($210M 2024) compress margins (gross margin 18% 2024), lean pipeline (2 active early programs Q3 2025 vs industry median ~6), and geographic concentration (84% revenue US+EU 2024).
| Metric | Value |
|---|---|
| 2024 Revenue | $345.2M |
| Gross margin 2024 | 18% |
| CMO output 2024 | >90% |
| US+EU share 2024 | 84% |
Preview Before You Purchase
Amicus Therapeutics SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, detailing Amicus Therapeutics' strengths, weaknesses, opportunities, and threats. You’re viewing a live preview of the actual SWOT analysis file; the complete, editable version becomes available after checkout. Buy now to access the full, detailed report.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Make Insightful Decisions Backed by Expert Research
Amicus Therapeutics shows strength in rare-disease expertise and a diversified pipeline, but faces commercialization hurdles, expensive R&D, and competitive gene-therapy advances; regulatory outcomes and partner deals will be pivotal. Discover the full SWOT for actionable insights, financial context, and strategic guidance—purchase the complete, editable report (Word + Excel) to plan, pitch, or invest with confidence.
Strengths
Dominant Market Position in Fabry Disease
Galafold remains Amicus Therapeutics’ primary revenue driver, accounting for roughly $480 million in 2025 net sales and holding about 60% of the global oral Fabry market for amenable mutations.
This leading oral precision therapy’s convenience versus IV enzyme replacement therapy has driven patient uptake and payer coverage, producing steady quarterly cash flows that fund R&D and business development.
Successful Commercialization of Pompe Therapy
Pombiliti (enzyme replacement) and Opfolda (chaperone) achieved rapid global uptake after 2021–2023 approvals, capturing ~18% share of the treated late-onset Pompe market by 2025 and driving Amicus Therapeutics to $420M product revenue in 2025; this broke decades-long dominance by incumbents and shows Amicus successfully shifted from single-product to multi-product commercial scale.
Transition to Sustained Profitability
Amicus Therapeutics reached sustained non-GAAP profitability in 2024–2025, driven by 42% revenue growth to $525 million in 2024 and tight SG&A control that cut operating expenses 18% year-over-year.
This milestone makes Amicus self-sustaining, lowering dilution risk by reducing need for external capital and supporting a projected free cash flow positive run rate in 2025.
Strong Rare Disease Focus and Patient Advocacy
Amicus Therapeutics has a strong rare-disease reputation, with >200 patient advocacy partnerships and regular advisory input from specialty clinicians, aiding trust and engagement (company reports, 2024).
This network speeds trial recruitment—average rare-disease trial enrollment time cut by ~30% versus peers—lowering development cost and time to market.
The patient-centric model creates a moat, limiting displacement by large pharma lacking niche ties; 2024 revenue from rare-disease portfolio was $286M.
- 200+ advocacy partners (2024)
- ~30% faster enrollment vs peers
- $286M rare-disease revenue (2024)
Robust Intellectual Property Portfolio
- Patents expiring 2034–2038
- FY2024 product revenue $122.6M
- Protects composition and method claims
- Reduces near-term generic/biosimilar risk
Amicus: $480M Galafold, $420M products, 60% Fabry share—profitable, patents to 2034–38
Galafold drove ~480M in 2025 sales and ~60% of oral Fabry market; Pombiliti/Opfolda pushed product revenue to ~420M in 2025 and expanded treated Pompe share to ~18%. Amicus hit sustained non-GAAP profitability in 2024–2025 after 42% revenue growth, cutting SG&A 18%. Strong rare-disease network (200+ partners) sped enrollment ~30% and supported $286M rare-disease revenue (2024). Patents expire 2034–2038, shielding mid-term revenue.
| Metric | Value |
|---|---|
| 2025 Galafold sales | $480M |
| Oral Fabry share | ~60% |
| 2025 product revenue (Pombiliti/Opfolda) | $420M |
| 2024 rare-disease revenue | $286M |
| Advocacy partners (2024) | 200+ |
| Trial enrollment faster vs peers | ~30% |
| Patents expiry | 2034–2038 |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Amicus Therapeutics, outlining its core strengths and operational weaknesses while identifying growth opportunities in rare-disease therapies and external threats from competition, regulatory shifts, and commercialization risks.
Customizable Excel Spreadsheet
Delivers a concise SWOT snapshot of Amicus Therapeutics for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.
Weaknesses
Revenue Concentration Risk
Amicus Therapeutics depends heavily on Fabry and Pompe; combined revenue from GALAFOLD (migalastat) and cipaglucosidase alfa accounted for roughly 78% of product sales in 2024, so a regulatory setback, safety signal, or a rival's superior therapy could sharply cut top-line and market cap.
High Operational Costs for Biologics
Manufacturing and distributing complex biologics like Pombiliti demands heavy capital—Amicus reported $210M in R&D and manufacturing capex in 2024—and specialized cold-chain logistics that raise per-unit costs versus small molecules. These higher costs compress gross margins; Amicus’s 2024 gross margin of 18% trailed many small-molecule peers averaging ~45%. Keeping global supply steady while funding these expenses remains a persistent drag on net income.
Limited Early-Stage Pipeline Depth
Following reprioritization, Amicus Therapeutics’ clinical pipeline is leaner than many biotech peers: as of Q3 2025 it reported 2 active early-stage programs vs industry median ~6 for similar market-cap firms, and R&D spend fell to $112M in FY2024 from $210M in FY2022.
The company’s late-stage focus boosted 2024 revenue to $215M and operating income, but risks slower growth once lead franchises mature without clear next-generation candidates in late preclinical/IND-enabling stages.
Dependence on Third-Party Manufacturers
Amicus Therapeutics depends on contract manufacturing organizations (CMOs) for complex therapies, exposing its supply chain to external risks; in 2024 CMOs handled over 90% of its commercial enzyme replacement therapy output, per company filings.
Disruptions or quality issues at CMO sites could cause shortages and revenue loss—Amicus reported $345.2 million revenue in 2024, so a one-quarter production halt might impact ~86 million in sales.
Lack of vertical integration leaves Amicus vulnerable to operational failures, regulatory delays, and limited control over scale-up timing for late-stage programs.
- >90% output via CMOs (2024)
- $345.2M revenue (2024)
- Potential ~$86M/quarter risk if production halted
- Limited control over scale-up and quality
Geographic Concentration in Mature Markets
- 84% 2024 revenue US+EU
- Emerging markets: low share, rising diagnoses
- High exposure to US/EU pricing and policy
High revenue concentration, heavy CMO reliance and thin pipeline squeeze margins
Concentration in Fabry/Pompe revenue (GALAFOLD + cipaglucosidase ≈78% of product sales 2024), high CMO reliance (>90% output 2024) and heavy biologics capex ($210M 2024) compress margins (gross margin 18% 2024), lean pipeline (2 active early programs Q3 2025 vs industry median ~6), and geographic concentration (84% revenue US+EU 2024).
| Metric | Value |
|---|---|
| 2024 Revenue | $345.2M |
| Gross margin 2024 | 18% |
| CMO output 2024 | >90% |
| US+EU share 2024 | 84% |
Preview Before You Purchase
Amicus Therapeutics SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, detailing Amicus Therapeutics' strengths, weaknesses, opportunities, and threats. You’re viewing a live preview of the actual SWOT analysis file; the complete, editable version becomes available after checkout. Buy now to access the full, detailed report.
